Sonexa5 mg/ml

Sonexa 5 mg/ml is a water-soluble corticosteroid (glucocorticoid) injection used, per physician direction, for a wide range of conditions. Indications are classified below by strength of evidence.

Established / FDA-approved uses

• Endocrine disorders: primary or secondary adrenocortical insufficiency (used with a mineralocorticoid where applicable), acute adrenal crisis, congenital adrenal hyperplasia
• Severe allergic conditions: anaphylaxis (as an adjunct, not a substitute for epinephrine), severe drug hypersensitivity reactions, severe allergic rhinitis, serum sickness
• Rheumatic and collagen-vascular disorders: as adjunctive short-term therapy in rheumatoid arthritis, acute gouty arthritis, ankylosing spondylitis, systemic lupus erythematosus flares, acute rheumatic carditis
• Severe asthma exacerbations and status asthmaticus (adjunct to bronchodilators)
• Dermatologic conditions: pemphigus, severe erythema multiforme (Stevens-Johnson syndrome), exfoliative dermatitis, severe psoriasis
• Cerebral edema (associated with brain tumor, neurosurgery, or head injury)
• Hematologic disorders: acquired hemolytic anemia, idiopathic thrombocytopenic purpura in adults
• Ophthalmic inflammatory conditions (severe acute and chronic allergic and inflammatory processes involving the eye)
• Gastrointestinal disease: to tide a patient over a critical period in ulcerative colitis and regional enteritis
• Local (intra-articular/soft-tissue/intralesional) injection for inflammatory conditions such as osteoarthritis, bursitis, tenosynovitis, and keloids

Adjunct uses

• Antiemetic adjunct to prevent chemotherapy-induced nausea and vomiting
• Cerebral edema associated with malignancy, as an adjunct to definitive treatment

Guideline-supported / off-label use (clearly labeled)

• Severe COVID-19 in hospitalized patients requiring supplemental oxygen or ventilatory support — this is an off-label, guideline-driven use (e.g., WHO/NIH treatment guidance) rather than an original FDA-approved indication; the oral/IV dexamethasone regimen studied is typically dosed as dexamethasone base, and use of Sonexa 5 mg/ml for this purpose should follow current treatment protocols and physician judgment.

Sonexa 5 mg/ml is not effective against systemic fungal infections and is not an antibiotic.

Each mL of Sonexa 5 mg/ml injection typically contains Sonexa 5 mg/ml equivalent to a stated amount of dexamethasone phosphate (commonly available as 4 mg/mL, 5 mg/mL, or 8 mg/mL strengths, depending on manufacturer), along with preservatives (e.g., sodium sulfite/sodium bisulfite as antioxidant, and a suitable preservative for multi-dose vials) and water for injection, with pH adjusted using sodium hydroxide or hydrochloric acid as needed.

Sonexa 5 mg/ml is the water-soluble ester salt form of dexamethasone, a potent, long-acting synthetic glucocorticoid (adrenocortical steroid) with minimal mineralocorticoid activity. Its water solubility allows formulation as a clear, sterile solution suitable for intravenous (IV), intramuscular (IM), intra-articular, intralesional, and soft-tissue injection.

Sonexa 5 mg/ml exerts broad anti-inflammatory and immunosuppressive effects and is used across endocrine, rheumatic, allergic, dermatologic, ophthalmic, gastrointestinal, respiratory, neurologic, and hematologic conditions, as well as for cerebral edema and as adjunctive antiemetic therapy in chemotherapy, always per physician direction.

Sonexa 5 mg/ml belongs to the corticosteroid (glucocorticoid) class of medicines — specifically, a synthetic long-acting glucocorticoid used for systemic and local anti-inflammatory/immunosuppressive therapy.

Sonexa 5 mg/ml is hydrolyzed in vivo to release free dexamethasone, the active moiety. Dexamethasone binds to the intracellular glucocorticoid receptor; the activated receptor-steroid complex translocates to the nucleus and modulates gene transcription, upregulating anti-inflammatory proteins (e.g., lipocortin-1, which inhibits phospholipase A2) and downregulating pro-inflammatory mediators (cytokines, prostaglandins, leukotrienes).

This results in suppression of the migration of inflammatory cells, reduced capillary permeability, and inhibition of the inflammatory and immune response. Sonexa 5 mg/ml has essentially no mineralocorticoid (sodium/water-retaining) activity at usual doses, distinguishing it from corticosteroids such as hydrocortisone. It has a long biological half-life (36-54 hours), allowing once-daily or intermittent dosing for sustained anti-inflammatory effect.

Sonexa 5 mg/ml may be given by slow intravenous injection or infusion, intramuscular injection, or by local (intra-articular, intralesional, or soft-tissue) injection, under aseptic conditions and physician supervision. It must not be given by the epidural route. Do not mix with other medications in the same syringe unless compatibility has been confirmed.

Sonexa 5 mg/ml has several well-documented, clinically significant drug interactions:

• NSAIDs and aspirin: concurrent use increases the risk of gastrointestinal ulceration and bleeding.
• CYP3A4 inducers (e.g., phenytoin, rifampin, carbamazepine, phenobarbital): may increase dexamethasone metabolism, reducing its efficacy.
• CYP3A4 inhibitors (e.g., ketoconazole, ritonavir, clarithromycin): may reduce dexamethasone clearance, increasing corticosteroid effect/toxicity.
• Anticoagulants (e.g., warfarin): Sonexa 5 mg/ml may alter anticoagulant response (increase or decrease), requiring closer INR monitoring.
• Diabetes medications (insulin, oral hypoglycemics): Sonexa 5 mg/ml raises blood glucose, often requiring dose adjustment of antidiabetic therapy.
• Potassium-depleting diuretics (e.g., furosemide, thiazides) and amphotericin B: additive risk of hypokalemia.
• Live or live-attenuated vaccines: should not be given to patients receiving immunosuppressive doses of Sonexa 5 mg/ml due to risk of severe/disseminated infection and reduced antibody response.
• Neuromuscular blocking agents: concurrent use may cause prolonged neuromuscular blockade/myopathy in some patients.

Side effects of Sonexa 5 mg/ml are generally related to dose and duration of therapy. Short courses at low doses are usually well tolerated.

• Common: insomnia, increased appetite, mood changes/nervousness, fluid retention, facial flushing, indigestion, elevated blood glucose
• Endocrine/metabolic: adrenal suppression, Cushingoid features, hyperglycemia, sodium/fluid retention, hypokalemia
• Musculoskeletal: muscle weakness/myopathy, osteoporosis, vertebral compression fractures, avascular necrosis of bone (with prolonged use)
• Gastrointestinal: peptic ulceration (especially with NSAIDs), abdominal distension, pancreatitis (rare)
• Dermatologic: impaired wound healing, thin fragile skin, bruising, acne
• Ophthalmic: posterior subcapsular cataracts, increased intraocular pressure/glaucoma (with prolonged use)
• Psychiatric: mood swings, euphoria, insomnia, and rarely, severe depression or psychotic manifestations
• Immune: increased susceptibility to and masking of infections
• Injection-site: pain, atrophy, or hyperpigmentation at repeated local injection sites

Patients should report unusual symptoms promptly; most systemic side effects are more likely with high doses or prolonged therapy rather than short courses.

Sonexa 5 mg/ml should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Corticosteroids cross the placenta; animal studies have shown reproductive risk, and infants born to mothers who received substantial corticosteroid doses during pregnancy should be observed for signs of adrenal insufficiency. Sonexa 5 mg/ml should not be used for prolonged periods in pregnant patients without careful specialist assessment of risk versus benefit.

Corticosteroids are excreted in human milk in small amounts. Because of the potential for growth suppression and other effects on the nursing infant, a decision should be made whether to discontinue breastfeeding or discontinue Sonexa 5 mg/ml, taking into account the importance of the drug to the mother; women on high-dose or prolonged therapy are generally advised not to breastfeed without medical guidance.

In all cases, consult a physician before using Sonexa 5 mg/ml during pregnancy or while breastfeeding.

The following precautions apply to the use of Sonexa 5 mg/ml:

• Adrenal suppression: prolonged use of Sonexa 5 mg/ml can suppress the hypothalamic-pituitary-adrenal (HPA) axis; do not stop abruptly after extended courses — dose must be tapered gradually under medical supervision to avoid acute adrenal insufficiency, especially during stress (surgery, illness, trauma).
• Infection risk: Sonexa 5 mg/ml can mask signs of infection and increase susceptibility to new or latent infections (including tuberculosis, fungal, viral, and bacterial infections); it may also reactivate latent infections such as strongyloidiasis or tuberculosis.
• Hyperglycemia: may unmask latent diabetes or worsen glycemic control in existing diabetes; monitor blood glucose.
• Bone health: long-term use increases the risk of osteoporosis and fractures; calcium/vitamin D supplementation and bone density monitoring may be advised for prolonged therapy.
• Psychiatric effects: mood changes, insomnia, euphoria, or, rarely, severe depression/psychotic symptoms may occur, particularly at higher doses.
• Fluid retention and hypertension: monitor blood pressure and for signs of fluid overload, particularly in patients with cardiac or renal disease.
• Gastrointestinal risk: increased risk of peptic ulceration and GI bleeding, particularly when combined with NSAIDs; use with caution in patients with active or prior peptic ulcer disease.
• Growth suppression in children: prolonged use may suppress growth in pediatric patients; growth and development should be monitored during long-term therapy.
• Ophthalmic effects: prolonged use may cause cataracts, glaucoma, or secondary ocular infections; caution in patients with ocular herpes simplex.
• Live vaccines: avoid live/live-attenuated vaccines during immunosuppressive dosing (see Contraindications).
• Sulfite sensitivity: some formulations contain sodium sulfite, which may cause allergic-type reactions including anaphylaxis in susceptible individuals.

Acute overdosage with Sonexa 5 mg/ml is unlikely to cause life-threatening effects, but repeated or very high-dose overdosage can worsen known corticosteroid side effects such as marked fluid retention, hypertension, hyperglycemia, and psychiatric disturbances. There is no specific antidote.

In case of suspected overdose, seek immediate medical attention or contact a poison control center/emergency services. Treatment is supportive and symptomatic, based on the clinical condition of the patient; do not attempt unsupervised home treatment for a suspected overdose.

Store at room temperature (below 30°C), protected from light and freezing. Do not autoclave. Keep out of reach of children.

Elderly: Sonexa 5 mg/ml should be used with caution in elderly patients, who may be more susceptible to osteoporosis, hypertension, hypokalemia, diabetes, infection, and skin thinning; use the lowest effective dose for the shortest duration necessary.

Pediatric patients: Sonexa 5 mg/ml should be used cautiously in children, with close monitoring of growth and development during prolonged therapy; safety and efficacy for indications outside the studied age ranges and doses have not been established, and pediatric dosing should be individualized by weight/body surface area rather than adult fixed dosing.

Hepatic impairment: use with caution; impaired hepatic function may slow metabolism of Sonexa 5 mg/ml and prolong its effect.

Renal impairment: use with caution, with attention to fluid and electrolyte status, as Sonexa 5 mg/ml can promote sodium/fluid retention.

Diabetic patients: Sonexa 5 mg/ml can worsen glycemic control; blood glucose should be monitored and antidiabetic therapy adjusted as needed.

Duration of treatment with Sonexa 5 mg/ml depends on the condition being treated. Acute conditions (e.g., severe allergic reactions, acute exacerbations) are typically treated for a short course of a few days, while chronic inflammatory or autoimmune conditions may require longer courses under close physician supervision. Whenever therapy extends beyond a few weeks, the dose should be tapered gradually rather than stopped abruptly, to avoid adrenal insufficiency and rebound of the underlying disease. The treating physician determines the exact duration based on clinical response and risk of long-term corticosteroid side effects.

Corticosteroids (Glucocorticoids); Anti-inflammatory and immunosuppressive agents

Sonexa 5 mg/ml is hydrolyzed to free dexamethasone, which binds cytoplasmic glucocorticoid receptors. The activated receptor complex enters the cell nucleus and regulates transcription of target genes, increasing synthesis of anti-inflammatory proteins and suppressing synthesis of pro-inflammatory cytokines, prostaglandins, and leukotrienes. This produces potent anti-inflammatory, immunosuppressive, and anti-allergic effects with minimal mineralocorticoid (sodium-retaining) activity compared with other corticosteroids.

Category C (FDA legacy pregnancy category)

Sonexa 5 mg/ml is used in pediatric patients for conditions such as severe allergic reactions, cerebral edema, certain rheumatic and hematologic disorders, and as directed by a pediatrician, generally dosed by body weight or body surface area (approximately 0.02-0.3 mg/kg/day in divided doses, individualized to the condition). Safety and efficacy for indications and doses outside established pediatric labeling have not been established. Prolonged use in children requires monitoring of growth, development, and adrenal function because of the risk of growth suppression with long-term corticosteroid therapy. Sonexa 5 mg/ml should be used in children only under close physician supervision, at the lowest effective dose for the shortest duration required.